Cartesian Therapeutics Inc Profile last edited on: 6/10/2024
CAGE: 7NM42
UEI: PXGLS86SY6B1
Business Identifier: Novel cellular immunotherapies to cure cancer 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
704 Quince Orchard Road
Gaithersburg, MD 20878
Gaithersburg, MD 20878
| (301) 348-8698 |
| info@cartesiantx.com |
| www.cartesiantherapeutics.com |
Location: Single
Congr. District: 06
County: Montgomery
Congr. District: 06
County: Montgomery
Public Profile
Cartesian Therapeutics is abiotechnology company structured around immunotherapy. Originally developed by NIH researchers, the firm's proprietary technology, has the potential to greatly broaden the use of Chimeric Antigen Receptor (CAR) cells for patients with multiple myeloma and other diseases. Although treatment has improved significantly in the past two decades, nearly all patients eventually relapse, and the disease remains incurable. Chimeric antigen receptor (CAR) therapies are the primary focus of Cartesian personnel; and the firm's lead product: Descartes-08,
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
25-49Revenue Range
2.5M-5MVC funded?
YesPublic/Private
Publicly TradedStock Info
NASDAQ : RNACIP Holdings
5-9Awards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 1742294281 | 2 | NIH | $149,009 | |
| Project Title: Targeting BCMA+ Cells with RNA-engineered CAR T cells to treat Lupus: A Phase 2 clinical study | ||||
| 1742228424 | 2 | NIH | $1,496,119 | |
| Project Title: Manufacturing RNA-based CAR T cells to combat autoantibody-associated autoimmune disorders (AAAD) | ||||
| 2022 | 2 | NIH | $1,998,234 | |
| Project Title: Phase 1/2a Clinical Study of Descartes-30 in Acute Respiratory Distress Syndrome | ||||
| 2021 | 2 | NIH | $1,990,216 | |
| Project Title: Autologous T-Cells Expressing a Chimeric Antigen Receptor Directed to B-Cell Maturation Antigen (BCMA) in Patients with Generalized Myasthenia Gravis (MG) | ||||
| 2021 | 2 | NIH | $2,275,494 | |
| Project Title: Transient ANTI-BCMA Car T-Cells for Treatment of Multiple Myeloma | ||||
Key People / Management
Carsten Brunn -- President and CEO
Kristen Baldwin -- Chief People Officer
Matthew Bartholomae -- General Counsel Secretary
Albina Benson -- Senior Director Manufacturing
Blaine Davis -- Chief Financial Officer
Emily English -- Vp Quality Assurance
Christopher M Jewell -- Chief Scientific Officer
Murat Kalayoglu -- President and CEO
Metin Kurtoglu -- Chief Operating Officer
Milos Miljkovic -- Chief Medical Officer
Charles Andrew Stewart -- VP Research
Yi Zhang -- Senior Director Technology
Kristen Baldwin -- Chief People Officer
Matthew Bartholomae -- General Counsel Secretary
Albina Benson -- Senior Director Manufacturing
Blaine Davis -- Chief Financial Officer
Emily English -- Vp Quality Assurance
Christopher M Jewell -- Chief Scientific Officer
Murat Kalayoglu -- President and CEO
Metin Kurtoglu -- Chief Operating Officer
Milos Miljkovic -- Chief Medical Officer
Charles Andrew Stewart -- VP Research
Yi Zhang -- Senior Director Technology
